

Docket No.: PF-0059-5 CON

1. (Once Amended.) A purified polypeptide comprising an amino acid sequence selected from the group consisting of:

- B<sup>1</sup>
- a) the amino acid sequence of SEQ ID NO:2,
  - b) a naturally-occurring amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:2,
  - c) a biologically active fragment of the polypeptide having the amino acid sequence of SEQ ID NO:2, and
  - d) an immunogenic fragment of the polypeptide having the amino acid sequence of SEQ ID NO:2.

2. (Once Amended.) An isolated polypeptide of claim 1, having the amino acid sequence of SEQ ID NO:2.

24. A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:

- N.E.
- a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
  - b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

28. An isolated antibody which specifically binds to a polypeptide of claim 1.

29. (Once Amended.) A diagnostic test for a condition or disease associated with the expression of GIPL in a biological sample comprising the steps of:

- B<sup>2</sup>
- a) combining the biological sample with an antibody of claim 28, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex; and
  - b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

30. The antibody of claim 28, wherein the antibody is:

- N.E.
- a) a chimeric antibody,

102170

2

09/875,520

Docket No.: PF-0059-5 CON

- N.E.
- b) a single chain antibody,
  - c) a Fab fragment,
  - d) a F(ab')<sub>2</sub> fragment, or
  - e) a humanized antibody.

31. A composition comprising an antibody of claim 28 and an acceptable excipient.

B<sup>3</sup>

32. (Once Amended.) A method of diagnosing a condition or disease associated with the expression of **GIPL** in a subject, comprising administering to said subject an effective amount of the composition of claim 31.

N.E.

33. A composition of claim 31, wherein the antibody is labeled.

34. (Once Amended.) A method of diagnosing a condition or disease associated with the expression of **GIPL** in a subject, comprising administering to said subject an effective amount of the composition of claim 33.

B<sup>4</sup>

35. (Once Amended.) A method of preparing a polyclonal antibody with the specificity of the antibody of claim 28 comprising:

- a) immunizing an animal with a polypeptide having the amino acid sequence of SEQ ID NO:2, or an immunogenic fragment thereof, under conditions to elicit an antibody response;
- b) isolating antibodies from said animal; and
- c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having the amino acid sequence of SEQ ID NO:2.

36. An antibody produced by a method of claim 35.

N.E.

37. A composition comprising the antibody of claim 36 and a suitable carrier.

D cket N .: PF-0059-5 CON

38. (Once Amended.) A method of making a monoclonal antibody with the specificity of the antibody of claim 28 comprising:

- B<sup>5</sup>
- a) immunizing an animal with a polypeptide having the amino acid sequence of SEQ ID NO:2, or an immunogenic fragment thereof, under conditions to elicit an antibody response;
  - b) isolating antibody producing cells from the animal;
  - c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells;
  - d) culturing the hybridoma cells; and
  - e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having the amino acid sequence of SEQ ID NO:2.

39. A monoclonal antibody produced by a method of claim 38.

40. A composition comprising the antibody of claim 39 and a suitable carrier.

U.E.

41. The antibody of claim 28, wherein the antibody is produced by screening a Fab expression library.

42. The antibody of claim 28, wherein the antibody is produced by screening a recombinant immunoglobulin library.

43. (Once Amended.) A method for detecting a polypeptide having the amino acid sequence of SEQ ID NO:2 in a sample, comprising the steps of:

- B<sup>4</sup>
- a) incubating the antibody of claim 28 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and
  - b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having the amino acid sequence of SEQ ID NO:2 in the sample.

44. (Once Amended.) A method of purifying a polypeptide having the amino acid sequence of SEQ ID NO:2 from a sample, the method comprising:

**Docket No.: PF-0059-5 CON**

- B<sup>u</sup> cont'd*
- a) incubating the antibody of claim 28 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and
  - b) separating the antibody from the sample and obtaining the purified polypeptide having the amino acid sequence of SEQ ID NO:2.
-